Navigation Links
Ontario Genomics Institute invests in validation of a novel protein interaction technology at U of T
Date:11/1/2012

TORONTO, ON, Nov. 1, 2012 - Every process in a cell is affected by interactions between proteins. Understanding how proteins react in the human body and their relationship to diseases is essential to the development of new and better targeted therapies. The Ontario Genomics Institute (OGI) is providing $100,000 through its Pre-commercialization Business Development Fund (PBDF) to the University of Toronto (U of T)'s Mammalian Membrane Two-Hybrid (MaMTH) project, which seeks to develop and commercialize a process to better understand membrane proteins in mammalian cells.

Dr. Igor Stagljar and his research team at U of T have developed a technology to analyze protein-protein interactions of mammalian integral membrane proteins. Membrane proteins, which make up approximately one-third of all proteins in a cell, are responsible for a variety of processes, making them attractive therapeutic targets. However, they are difficult to study because of their chemical complexity. This translational research tool will allow researchers to study interactions between membrane proteins of interest and how they respond to various therapeutic compounds in the context of the human cell.

"This tool has the potential to improve drug development and expand the resources available to companies developing new therapeutics," said Dr. Mark Poznansky, President and CEO, Ontario Genomics Institute. "Investment in projects like Dr. Stagljar's demonstrate OGI's commitment to fostering a vibrant life sciences community in Ontario."

Proteomic technologies such as MaMTH are increasingly playing key roles in the fields of medicine, drug discovery and molecular diagnostics. This tool has garnered attention from industry, who plan to license the technology if the project is successful. OGI's funding is essential for the development and validation necessary to make this assay commercially viable.

"We are pleased to receive this funding from OGI, which comes at a critical time as we commercialize our assay," said Dr. Stagljar, Professor, U of T. "There is strong demand for technologies like MaMTH from both academia and pharmaceutical companies, and this funding will enable us to make the final step in bringing this tool to market."

"The MaMTH project is a great example of an effective partnership between researchers working with their academic institution and key strategic partners, to benefit the research community and translate a technology to industry," said Ian Stewart, Senior Manager, Commercialization and Business Development, the Innovations and Partnerships Office at U of T.

OGI's PBDF program invests in opportunities based in genomics, proteomics or associated technologies that fall in the proof-of-principle (validation) phase of research and have the short-term potential to secure a significant next step towards the marketplace. Previous recipients have included Ontario universities, research institutes and companies.


'/>"/>

Contact: Christine Beyaert
cbeyaert@ontariogenomics.ca
416-673-6597
Ontario Genomics Institute
Source:Eurekalert

Related biology news :

1. New genomics study shows ancestry could help solve disease riddles
2. Physiological Genomics journal announces a major restructuring
3. 2 pioneering plant genomics efforts given a funding boost by National Science Foundation
4. ShanghaiBio Corporation Partners with Ingenuity Systems to Address Challenges in Analysis and Interpretation of Genomics Data
5. Elsevier launches new open access journal: Applied and Translational Genomics
6. The genomics symposium to boost the further development of cancer research
7. ACRG and BGI report findings from genomics research on recurrent hepatitis B virus integration
8. In search for a vaccine, IU biologist receives $2.3 million to explore chlamydia genomics
9. BGI, University of Helsinki and Wuhan University sign a MOU concerning cooperation on genomics
10. SDSCs big data expertise aiding genomics research
11. Reducing radiation: Heart Institute model shows hope for new standards worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):
(Date:7/20/2017)... ... July 20, 2017 , ... Dr. Asher Kimchi, Founder ... recipients of the 2017 IAC Awards at the 22nd World Congress on Heart Disease ... named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together ...
(Date:7/20/2017)... ... July 20, 2017 , ... VIC Technology Venture Development™ ... company’s board of directors. This addition continues to strengthen and diversify VIC’s board. ... CEO and Chairman. “He is a highly accomplished business executive with a broad range ...
(Date:7/20/2017)... 2017   KCNQ2 Cure Alliance  and ... today announced that they have completed the first ... implicated in KCNQ2 epileptic encephalopathy. They also report ... case involving an additional KCNQ2 genetic mutation. ... Pairnomix entered into a collaboration to further explore ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... make clinical trial sites and study participants truly unified. TrialKit, a native mobile ... 21 CFR Part 11) research studies entirely on mobile devices. With TrialKit, clinical ...
Breaking Biology Technology: